银休特（Insulet，股票代码：PODD）在盘后交易中大幅上涨10.89%，引发市场关注。这一显著涨幅主要归因于公司公布的第一季度财报优于市场预期。
银休特是一家专注于可穿戴式胰岛素泵生产的医疗设备公司。其主打产品Omnipod是一种无需外部管道的自动胰岛素输送设备，深受糖尿病患者欢迎。公司的Omnipod 5系统是首个获准用于管理1型和2型糖尿病的系统，显示了其在市场中的领先地位。尽管市场对新型糖尿病和减肥药物（GLP-1s）需求激增可能影响胰岛素泵销售存在担忧，但银休特的业绩表现有力地回应了这些疑虑。
财报显示，银休特第一季度总收入同比增长28.8%，达到5.69亿美元，超过分析师预期的5.434亿美元。其中，Omnipod胰岛素泵的销售额达到5.541亿美元，同样高于市场预期。公司调整后每股收益为1.02美元，大幅超过分析师平均预期的0.80美元。基于强劲的业绩表现，银休特上调了全年收入增长预期，从此前的16%到20%提高至19%到22%，进一步提振了投资者信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.